Spectrum Academy
Keep moving forward
Take advantage of the further education and training opportunities
offered by the Dr. Erkens Consulting Group
Spectrum-Academy
The range of services offered by the Dr. Erkens Consulting Group includes the conception and carrying out of various information and training events as well as education and training programmes. We have bundled this as a further business line of the Dr. Erkens Consulting Group, under the umbrella of the Spectrum Academy.
Subject Areas
The main topics of the Spectrum Academy’s further education and training programme are essentially oriented towards the business areas of the Dr. Erkens Consulting Group.
Analysis | Market Research
Strategy | Implementation
Marketing | Sales
Communication | Education
Organisation | Processes
Innovation | Leadership
Formats
The constantly evolving event portfolio includes:
- Individually designed in-house events at our clients’ premises
- Centrally organized practice-oriented seminars and interactive workshops
- Online events and training courses
Target group
Our offer is specifically aimed at professionals from the healthcare, medical, pharmaceutical, medtech and life sciences industries. It is rounded off by special training courses for employees of companies from the above-mentioned sectors and start-ups, and medical events for patients.
Partners
The Spectrum Academy is supported and co-sponsored by longstanding and trustworthy partner companies such as the be-sign.net agency (which specialises in print and web design) and Aurum Research (which examines the international healthcare market).
Anschrift
Dr. Erkens Consulting Group
Industriestraße 13
64380 Roßdorf
Tel: +49 (0)6154 – 6967 – 944
Mobil +49 (0)179 – 2 41 10 29
info@dr-erkens-consulting.de
Social
News
Dr. Erkens Consulting Group
- Neue Website der Dr. Erkens Consulting Group geht online
Source: Dr. Erkens Consulting Group 09/2020 - Integrierte Pharma-News auf der Dr. Erkens Consulting Group Website
Source: Dr. Erkens Consulting Group 09/2020
Pharma Letter
- The week in pharma: action, reaction and insight – week to March 14
- Regenxbio completes its BLA filing for first potential gene therapy for MPS II
- Fosun Pharma to sell hospital group stake for $124 million
- Ellipses Pharma: the drug development model that minimizes risk
- First IGF-1R antibody for thyroid eye disease in China
Pharma Relations
Pharma Times
- Rxulti approved in the European Union for adolescent schizophrenia
- Grifols clinical trial shows positive results for post-polio patients
- Minoryx doses first patient with leriglitazone in Rett syndrome study
- Orphelia Pharma explores other pathways for paediatric cancer treatment
- Dementia drug neflamapimod shows positive phase 2b trial results
PZ online
- Ranking: Das sind die häufigsten Symptome der Wechseljahre
- Koalitionsverhandlungen: CSU will Apothekenthemen setzen
- Erfolgreiche Petitionen : Hunderttausende Unterschriften für Apotheken und Praxen
- Pollenallergie: Fünf Tipps zum Start der Heuschnupfen-Saison
- Diskussion in Schwerin : Ein Tsunami bedroht das Gesundheitssystem
Our Place on Earth
Kartenbild: OpenStreetMap, ODbL 1.0